TSLA Stock Jumps 3% Ahead Of Q2 Report — Analysts Split On Earnings Beat Expectations And Tesla’s Overpromise Problem

Gene Munster forecasts Tesla automotive gross margins slightly above the Street’s 19.5% estimate.
Tesla's Optimus robot serving popcorn at a Berlin shopping mall. (Photo by Christoph Soeder/picture alliance via Getty Images)
Tesla's Optimus robot serving popcorn at a Berlin shopping mall. (Photo by Christoph Soeder/picture alliance via Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Published Jul 21, 2026   |   8:20 PM EDT
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...
  • Munster flagged higher capital spending as a key variable. 
  • Gary Black argues that repeated missed public timelines on Robotaxi have damaged Tesla’s management credibility.
  • Tesla is likely to answer investor queries on robotaxi deployment, Optimus production ramp and queries regarding market speculation of a likely Tesla-SpaceX merger on the earnings call.

Advertisement|Remove ads.

As Tesla Inc. (TSLA) prepares to report second-quarter 2026 results after the market close on Wednesday, two analysts weighed in with contrasting but complementary takes on the electric vehicle maker’s near-term momentum and longer-term communication challenges.

TSLA stock closed up by about 3% on Tuesday after four consecutive days of losses.  

Read Next
Loading...
Loading...

Munster: Solid Deliveries, Rising Capex Ahead

Gene Munster of Deepwater Asset Management forecasts Tesla’s automotive gross margins, excluding credits, slightly above the Street’s 19.5% estimate, supported by the company’s nearly 480,000 deliveries during the period, up 25% year over year and well above consensus.

Advertisement|Remove ads.

Munster flagged higher capital spending as a key variable, projecting $6.7 billion in Q2 capex and warning that full-year guidance could rise above the current $25.6 billion consensus. He also expects Cybercab volume production to shift into the first half of 2027 rather than late 2026.

“Overall, I expect good news, just don’t know how investors will take greater capex for CY27.” Munster wrote. In April, Tesla raised its 2026 capex guidance to more than $25 billion, up from a prior target of nearly $20 billion. The company has not provided any figures for 2027 yet.  

Black: Overpromise Problem Hurts Credibility

Gary Black of The Future Fund argued in a post on X that repeated missed public timelines on Robotaxi have damaged Tesla’s management credibility.

Advertisement|Remove ads.

Black highlighted several examples, including Elon Musk’s Q2 2025 claim that half the U.S. population would be covered by Robotaxi by year-end — a target still far from reality.

Black argued that while few doubt Tesla’s underlying technology edge over competitors like GM and Ford, the pattern of aggressive public forecasts followed by shortfalls has created “new, unnecessary attack vectors and disillusionment.” He called for improved communications, suggesting Elon Musk “needs to bring on 1-2 adults to shore up credibility.”

Meanwhile, according to a compilation of questions raised by Tesla investors on Say Technologies, the company is likely to answer investor queries on robotaxi deployment, Optimus production ramp, and market speculation of a likely Tesla-SpaceX merger on the earnings call.

Advertisement|Remove ads.

How Did TSLA Retail Traders React?

On Stocktwits, retail sentiment around TSLA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.

According to Tesla’s company-compiled consensus estimates, Wall Street expects the company to report total Q2 revenue of about $27.58 billion, marking a year-on-year jump of about 23%, and adjusted earnings per share of $0.55, higher than the $0.40 reported in Q2 2025.

TSLA stock has fallen 16% year-to-date.

Advertisement|Remove ads.

Read More: Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Comments
Share your thoughts...

Comments posted here will also appear on symbol pages.

Follow on Google News
Read about our editorial guidelines and ethics policy

Advertisement|Remove ads.